Antibody therapeutics targeting novel tumor specific biomarkers
※ Slide it to the side
| Pipeline | MoA | Indication | Development stage | ||||
|---|---|---|---|---|---|---|---|
| Discovery | Candidate | Non-clinical | Phase 1 | Phase 2/3 | |||
| ED1 (neutralizing antibody) |
TME | Colorectal Cancer |
|
||||
| ED2 (antibody-drug conjugate) |
TME Cancer cell |
Colorectal Cancer |
|
||||
| Sarcoma |
|
||||||
| Pancreatic/ Ovarian Cancer |
|
||||||
| ED3 (Bi-specific antibody) |
TME Cancer cell |
Solid tumor |
|
||||
| ED4 (bi-specific ADC) |
TME Immune cell infiltration |
Solid tumor |
|
||||